Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study-Reference-Cited by-同舟云学术

Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study

Published:2015-07-14 Issue:5 Volume:21 Page:e369-e374
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Rodriguez V.¹,Mancuso M. E.²,Warad D.¹,Hay C. R. M.³,DiMichele D. M.⁴,Valentino L.⁵,Kenet G.⁶⁷,Kulkarni R.⁸

Affiliation:

1. Mayo Clinic Comprehensive Hemophilia Center; Rochester MN USA

2. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center; Fondazione IRCCS Ca’ Granda; Ospedale Maggiore Policlinico; Milan Italy

3. Department of Haematology; Manchester University; Manchester Royal Infirmary; Manchester UK

4. Weill Cornell Medical College; New York NY USA

5. Rush Hemophilia and Thrombophilia Center; Rush University Medical Center; Chicago IL USA

6. National Hemophilia Center; Sheba Medical Center; Tel Hashomer Israel

7. Sackler Medical School; Tel Aviv University; Tel Hashomer Israel

8. MSU Center for Bleeding and Clotting Disorders; Michigan State University; East Lansing MI USA

Funder

Baxter Bioscience

Bayer Healthcare

Biogen

CSL Behring

GTC Biotherapeutics

Inspiration Bioscience

Novo Nordisk

Pfizer

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12740/fullpdf

Reference32 articles.

1. The hemophiliac - From royal genes to gene therapy;Mannucci;N Engl J Med,2001

2. Consensus perspectives on prophylactic therapy for haemophilia: summary statement;Berntorp;Haemophilia,2003

3. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B;Nilsson;J Intern Med,1992

4. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review;Iorio;J Thromb Haemost,2010

5. Incidence of development of factor VIII and factor IX inhibitors in haemophilias;Ehrenforth;Lancet,1992

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Minor surgical procedures during immune tolerance induction in people with hemophilia A and inhibitors: results from the Brazilian Immune Tolerance (BrazIT) study cohort;Hematology, Transfusion and Cell Therapy;2024-09

2. Immune tolerance induction experience from a single institute in the United Arab Emirates;Journal of Applied Hematology;2022

3. Comparison of perioperative practices for placement of central venous access devices (CVAD) in children with haemophilia;The Journal of Haemophilia Practice;2022-01-01

4. Is immune tolerance induction conceivable in haemophilia with inhibitors in a low‐middle income country? Real‐world data from Tunisia;Haemophilia;2021-11-24

5. Emerging drugs for hemophilia A: insights into phase II and III clinical trials;Expert Opinion on Emerging Drugs;2021-10-02